Anna Piankova, M.D., Ph.D.

Associate Medical Director

Anna Piankova, M.D., Ph.D.

Associate Medical Director

Anna Piankova, M.D., Ph.D. has 10+ years of experience in clinical research, including a focus on CNS and Psychiatric indications for the past 6 years. In a recent Phase II study in Schizophrenia, enrollment speed in the region allocated to Dr. Piankova as Project Lead significantly exceeded the global figures. This was the result of a thorough site feasibility process, a deep understanding of the patient population, their standard of care and common enrollment barriers. Dr. Piankova is familiar with common scales and assessments, as well as the different methods of their completion: on paper and on tablets with audio and video recording. Her knowledge of this complex therapeutic area allows her to evaluate risks and implement timely mitigations that can save time and budget and ensure quality.  Dr. Piankova has overcome challenges such as poor patient compliance and retention, which is a common challenge in psychiatric clinical trials. She also maintains strong relationships with high-performing sites through peer-to-peer communication with investigators. Dr. Piankova obtained her MD, PhD degrees in Endocrinology from the Institute of Internal and Preventive Medicine in Russia. Her medical knowledge, clinical operations experience and strong analytical skills ensure high quality clinical trials that are delivered on-time and on-budget.

Why Clinical Research?

“At the beginning of my career in clinical research in 2013, I was involved in a metastatic non-small cell lung cancer trial. The expected median survival rate for patients treated with the standard of care at that time was only 7 months. The design of that study allowed patients to continue treatment if the study drug was effective for them, which was measured by no signs of disease progression. In 2023, patients who are continuing in that study have been in remission 10 years. While this is a happy story for those patients and their families, there are many other people and families who are faced with severe disease and wish for just such a happy outcome. I understand this personally, as there was no drug like this available when my mom was diagnosed with cancer. Clinical research is the mandatory step before medication becomes available for patients with life-threatening diseases. I am very proud to be part of this industry and to have the ability to contribute to this process.”